"She reported a clear improvement on most ME/CFS symptoms during the next days, which she described to be remarkably alike the response she had previously experienced from 6-7 weeks after Rituximab"
Thus, the administration of a NO donor surprisingly allow a treatment of CFS patients for immediate relief of symptoms without any delay as described for e.g. a B-cell depleting agent, like Rituximab, before.
Thus, the administration of a NO donor surprisingly allow a treatment of CFS patients for immediate relief of symptoms without any delay as described for e.g. a B-cell depleting agent, like Rituximab, before.
Thanks to Tate for passing this on. This lady was one of the Fluge/Mella's original lymphoma patients with ME/CFS. She found that Ritxumab cleared up her cancer and her ME/CFS but she relapsed after she went off the Rituximab.
Now lightning has struck again. She checked into the hospital for transient ischemic heart pain and upon receiving isosorbide mononitrate (Imdur®) she experienced significant symptom relief from her ME/CFS as well.
Imdur reduces blood pressure and is used in the treatment of angina. Essentially it dilates the blood vessels - letting the blood flow more freely.
Fluge and Mella appear to be using this combination: An alternative strategy was applied, using supplement with relatively high doses of L-Arginine 5 g twice daily combined with L-Citrulline 200 mg twice daily. They note that other combinations may work:
"Examples thereof include compounds inhibiting arginase, e.g. arginase II, a competitor of the NO synthase (NOS). Other examples comprise compounds stimulating the activity of NO synthase, in particular, of the eNOS, either by increasing the amount or level of NOS or the turn over rate of the enzyme." Plus they discuss using it in combination with Rituximab.
They treated six patients and found a moderate response in all of them. The idea of dilating the blood vessels seems to make sense in FM and ME/CFS. (Lowering blood pressure does not - I don't think). Fluge and Mella believe ME/CFS may be an autoimmune disorder that attacks the blood vessels. I certainly hope they are right and this woman's experience suggests they may be - at least for her. An autoimmune treatment (rituximab) and blood vessel dilator achieved the same results. That's very interesting!
https://data.epo.org/publication-server/pdf-document/EP13168487NWA1.pdf?PN=EP2805730 EP 2805730&iDocId=7868378&iepatch=.pdf
EUROPEAN PATENT APPLICATION Nitric oxide donor for the treatment of chronic fatigue syndrome - Inventors: Fluge, Oystein; Mella, Olla
In particular, the present inventors recognized that an immediate relief after administration of an NO donor can be observed. In contrast to medication administered so far for treatment of CFS, which are characterized by a remarkable lag time of treatment success, as described for example for the treatment with Rituximab or Methotrexate, see e.g. WO 2009/083602.
Thus, the administration of a NO donor surprisingly allow a treatment of CFS patients for immediate relief of symptoms without any delay as described for e.g. a B-cell depleting agent, like Rituximab, before. An alternative strategy was applied, using supplement with relatively high doses of L-Arginine 5 g twice daily combined with L-Citrulline 200 mg twice daily. L-Arginine is the sole substrate of Nitric Oxide Synthases (NOS), thus this approach aims to overcome the dysregulated nitric oxide system in CFS/ME patients by providing relatively high doses of the substrate.
Index observation
The patient was a 48 years old woman with previous thyroiditis. She had ME/CFS following mononucleosis in 1997 (33 years of age). She had a Hodgkin lymphoma stage II-A in 2003, and experienced in 2004 a transient response of her ME/CFS symptoms after chemotherapy for lymphoma relapse which has been described [Fluge O, Mella O (2009) BMC Neurol 9:28], and which later led to a pilot case series using Rituximab, also with a major but transient responses of ME/CFS symptoms for this patient.
After high-dose chemotherapy with autologous stem cell support, she has been relapse-free from lymphoma since 2006. In autumn 2012, she was admitted to a local hospital with a transient ischemic attach with paresis in left side of 30 minutes duration. She had previously received radiotherapy to the mediastinum and neck as treatment for limited-stage Hodgkin lymphoma, and due to a reduced left ventricular function, her cardiologist started oral isosorbide mononitrate (Imdur®) 30 mg which she received for five days before cessation of the therapy.
She had headache and some dizziness the first days, but also noticed an initial response of her ME/CFS symptoms starting within the first 24 hours. She reported a clear improvement on most ME/CFS symptoms during the next days, which she described to be remarkably alike the response she had previously experienced from 6-7 weeks after Rituximab infusion (as a pilot patient in 2007). After Imdur® treatment was stopped on day five, the symptom improvement vanished during the following two days, consistent with a direct symptomatic effect on her ME/CFS disease.
Last edited: